Dermatology

Goal disorientation and lack of vision
Biotech

Evommune’s phase 2b flops, ending challenge to Novartis in hives

A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for a skin disease market.
Nick Paul Taylor Jun 29, 2026 10:00am
skin cells epidermis layers lotion serum

Leo pays $50M for Replay and its skin disease gene therapy

Apr 30, 2026 9:00am
dynamic arrows moving up

Priovant will move brepocitinib to phase 3 after midstage win

Feb 6, 2026 7:00am
new york stock exchange
Favicon Fierce Pharma

Veradermics locks in $256M IPO, shares spike

Feb 5, 2026 10:01am
planet hoth ice space sky sun cave cold freezing outerspace

Hoth strikes back against skin toxicities but stock stays frozen

Jan 22, 2026 10:38am
Leo
Favicon Fierce Pharma

JPM26: Leo Pharma sharpens its eye for dermatology dealmaking

Jan 13, 2026 2:45pm